In RaDaR, stronger decreases in proteinuria was associated with:1
Slower rate of eGFR loss
Lower risk of kidney failure or death
RISK PREDICTION
In the RaDaR IgA nephropathy (IgAN) cohort,* time-averaged proteinuria is a strong, graded, and independent predictor of kidney outcomes, with risk evident even at low levels1
Patients traditionally regarded as being low risk, with proteinuria <0.88 g/g (<100 mg/mmol), had high rates of kidney failure within 10 years in the RaDaR study.1
The 2025 KDIGO guidelines define IgAN patients at risk of progressive loss of kidney function as those with proteinuria ≥0.5 g/day (or equivalent) while on or off treatment of IgAN. Treatment or additional treatment should be considered in all such cases.2
REDUCING PROTEINURIA IS ASSOCIATED WITH IMPROVED PATIENT OUTCOMES
FIND OUT MOREThe International Risk Prediction Tool for IgAN can help identify patients at high risk of disease progression2–4
International Risk Prediction Tool for IgAN can be used:3,4
The International Risk Prediction Tool for IgAN is recommended by the most recent KDIGO guidelines and uses a variety of clinical parameters to predict disease progression3,4
The MEST-C (mesangial and endocapillary hypercellularity, segmental sclerosis, interstitial fibrosis/tubular atrophy, and crescents) score is a histopathological scoring system for patients with IgAN. The MEST-C score should be determined at the time of biopsy and is an important practice point for the diagnosis of IgAN2